Advaxis Announces Voting Results of 2013 Annual Meeting of Stockholders

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced voting results from the Company's Annual Meeting of Stockholders, which was held in Princeton, NJ on June 14, 2013.

Stockholders supported the election of incumbents Thomas A. Moore, Roni A. Appel, Richard Berman, Dr. Thomas McKearn, and Dr. James Patton to the Board of Directors. Stockholders also ratified Marcum, LLP as the independent registered accountants for fiscal 2013.

Stockholders voted to approve the effect of a reverse stock split at the discretion of the Board of Directors at a ratio ranging from 1-for-70 to 1-for-125, the final ratio to be determined at the discretion of the Board of Directors. Stockholders also voted to approve a decrease of the authorized shares of capital stock of the Company on a post-reverse stock split basis.

Stockholders voted to approve the non-binding advisory vote on named executive officer compensation as disclosed in the Company's 2013 proxy statement. Stockholders also voted to approve the inclusion of an advisory vote on the compensation of the Company's named executive officers in the Company's proxy statement every three calendar years.

The voting results of each of these proposals will be disclosed in a report to be filed with the Securities and Exchange Commission.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn